Cargando…
Reversible Resistance Induced by FLT3 Inhibition: A Novel Resistance Mechanism in Mutant FLT3-Expressing Cells
OBJECTIVES: Clinical responses achieved with FLT3 kinase inhibitors in acute myeloid leukemia (AML) are typically transient and partial. Thus, there is a need for identification of molecular mechanisms of clinical resistance to these drugs. In response, we characterized MOLM13 AML cell lines made re...
Autores principales: | Weisberg, Ellen, Ray, Arghya, Nelson, Erik, Adamia, Sophia, Barrett, Rosemary, Sattler, Martin, Zhang, Chengsheng, Daley, John F., Frank, David, Fox, Edward, Griffin, James D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3182213/ https://www.ncbi.nlm.nih.gov/pubmed/21980431 http://dx.doi.org/10.1371/journal.pone.0025351 |
Ejemplares similares
-
Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase
por: Weisberg, Ellen L., et al.
Publicado: (2017) -
The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations
por: Weisberg, Ellen, et al.
Publicado: (2020) -
Dual inhibition of AKT/FLT3-ITD by A674563 overcomes FLT3 ligand-induced drug resistance in FLT3-ITD positive AML
por: Wang, Aoli, et al.
Publicado: (2016) -
Further Activation of FLT3 Mutants by FLT3 Ligand
por: Zheng, Rui, et al.
Publicado: (2011) -
HSP70 and FLT3-ITD: Targeting chaperone system to overcome drug resistance
por: Yang, Jing, et al.
Publicado: (2021)